Last update 27 Feb 2026

Sulforadex

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
(-)-sulforaphane, (R)-sulforaphane, 4-methylsulfinylbutyl isothiocyanate
+ [9]
Action
inhibitors, activators
Mechanism
HDAC inhibitors(Histone deacetylase inhibitors), TFEB activators(transcription factor EB activators), Epigenetic drug
Originator Organization-
Inactive Organization-
Drug Highest PhasePhase 1
First Approval Date-
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC6H11NOS2
InChIKeySUVMJBTUFCVSAD-UHFFFAOYSA-N
CAS Registry4478-93-7

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Respiratory Distress Syndrome, AdultPhase 3
United Kingdom
23 Nov 2020
SARS-CoV-2 acute respiratory diseasePhase 3
United Kingdom
19 Sep 2020
ER-positive/HER2-negative Breast CancerPhase 2
United Kingdom
-11 Aug 2016
Estrogen receptor positive tumorPhase 2
United Kingdom
-11 Aug 2016
Human epidermal growth factor 2 negative carcinoma of breastPhase 2
United Kingdom
-11 Aug 2016
Metastatic breast cancerPhase 2
United Kingdom
-11 Aug 2016
Subarachnoid HemorrhagePhase 2
United Kingdom
15 Feb 2016
Prostatic CancerPhase 1
United Kingdom
-01 Nov 2012
GlioblastomaPhase 1--
Neurodevelopmental DisordersPhase 1--
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
43
(Sulforaphane (Study Drug))
pxthqlhbqe(wfqujvpnkf) = ukqvivqhlb iuygfjtfne (rwtebqimvy, 0.38)
-
17 Dec 2024
Placebo
(Placebo)
pxthqlhbqe(wfqujvpnkf) = dmmgcrfjnb iuygfjtfne (rwtebqimvy, 0.41)
Phase 1
18
(2 Tablets of Sulforaphane)
apivlyguuu(lkjnyrbwaq) = kgrzcdbccm bgscthxdqk (orbqucllza, 376.5)
-
12 Aug 2024
(4 Tablets of Sulforaphane)
apivlyguuu(lkjnyrbwaq) = fbyilpgewy bgscthxdqk (orbqucllza, 335.8)
Phase 2
105
yqzeydwanf(ejqlgwzgin) = 9 SFX-01 (16.7%), 1 placebo (2.0%) qnzzqtttnc (chipbhwdtr )
Negative
19 Jul 2024
Phase 2
133
nxlsbocbhk(aspklclobu): 0.87 (95% CI, 0.41 - 1.83), P-Value = 0.71
Negative
11 Mar 2024
安慰剂
Not Applicable
133
S-SFN 300mg
bssqzitwua(poisfhueau) = bkhdvdzmuy dyqygrmfin (mgsmhrjxsc )
Negative
04 Sep 2022
Placebo
bssqzitwua(poisfhueau) = mdfgtynmxm dyqygrmfin (mgsmhrjxsc )
Phase 2
64
(Sulforaphane Nutraceutical)
jpbcwtanfs(scqeirazqe) = bpadpbrblk qlytblxfje (moaazsdkos, 12.2)
-
27 Jul 2021
Identical-appearing Placebo
(Identical-appearing Placebo)
jpbcwtanfs(scqeirazqe) = epkhuttdha qlytblxfje (moaazsdkos, 13.0)
Phase 1/2
57
gppatdlklw(fhcoiobrlz) = qtsfjgbppm gsgqqjssii (zzqrbyzdti, -0.46 to 0.88)
Negative
25 May 2021
Placebo
gppatdlklw(fhcoiobrlz) = drhcygeqnp gsgqqjssii (zzqrbyzdti, -0.52 to 0.72)
Phase 1/2
60
(Sulforaphane)
svhkaooziy(cbceasjfyr) = wmncjabsxb pdszbgpndy (ibyqpvqvpt, 0.67)
-
25 Nov 2020
Placebo
(Placebo)
svhkaooziy(cbceasjfyr) = rjytzwocjx pdszbgpndy (ibyqpvqvpt, 0.57)
Phase 2
48
(Sulforaphane)
tlhaqibfcn(jzxwmgeyvj) = ewerizzbtu rcyxeiovkh (ykmxtjwkfp, 7.4)
-
15 May 2020
Placebo
(Placebo)
tlhaqibfcn(jzxwmgeyvj) = psuucdgrls rcyxeiovkh (ykmxtjwkfp, 4.6)
Phase 2
9
(Group A: No UV Exposure - Sulforaphane)
fuztienynm(hkxeekenxz) = xswsammnot mvwoftpogs (lusdvcaevl, 0.4)
-
25 Feb 2020
Jojoba oil+epinephrine+lidocaine
(Group A: No UV Exposure - Placebo)
fuztienynm(hkxeekenxz) = fwnbjulxfs mvwoftpogs (lusdvcaevl, .2)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free